BRENDA - Enzyme Database show
show all sequences of 3.4.22.26

Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X

Kamocka, M.; Pollard, M.; Suckow, M.; Mielicki, W.P.; Rosen, E.D.; Comp. Med. 58, 282-286 (2008)

Data extracted from this reference:

Inhibitors
Inhibitors
Commentary
Organism
Structure
antiCP polyclonal antibody
-
Rattus norvegicus
antiFVIIa polyclonal antibody
-
Rattus norvegicus
Natural Substrates/ Products (Substrates)
Natural Substrates
Organism
Commentary (Nat. Sub.)
Natural Products
Commentary (Nat. Pro.)
Organism (Nat. Pro.)
Reversibility
additional information
Rattus norvegicus
cancer procoagulant is a cysteine protease acting as an activator of coagulation factor X, the protein activates factor X in the absence of tissue factor and factor VII
?
-
-
-
additional information
Rattus norvegicus
rat and human cancer procoagulant activity bind similarly to antiCP antibodies
?
-
-
-
Organism
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
Rattus norvegicus
-
Lobund-Wistar rat with transplanted PA-3 prostate tumors
-
Purification (Commentary)
Commentary
Organism
harvested PA3 tumors are extracted in 0.02 M Tris (pH 7.8), after centrifugation extracts are purified by ion-exchange chromatography, fractions containing CP activity are desalted and concentrated by ultrafiltration on YM10 membrane and redissolved in 2-3 ml of 0.02 M Tris
Rattus norvegicus
Source Tissue
Source Tissue
Commentary
Organism
Textmining
prostate gland cancer cell
prostate tumor
Rattus norvegicus
-
Specific Activity [micromol/min/mg]
Specific Activity Minimum [Ámol/min/mg]
Specific Activity Maximum [Ámol/min/mg]
Commentary
Organism
additional information
-
enzyme has procoagulant activity
Rattus norvegicus
0.059
-
crude extract from independent PA3 tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
0.068
-
crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
0.078
-
crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
0.082
-
crude extract from independent PA3 rat prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
0.098
-
crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
2.26
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 33fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
2.32
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 30fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
4.91
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 50fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
7.7
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 133fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
16.6
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 202fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
Substrates and Products (Substrate)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
additional information
cancer procoagulant is a cysteine protease acting as an activator of coagulation factor X, the protein activates factor X in the absence of tissue factor and factor VII
697471
Rattus norvegicus
?
-
-
-
-
additional information
rat and human cancer procoagulant activity bind similarly to antiCP antibodies
697471
Rattus norvegicus
?
-
-
-
-
Sar-Pro-Arg-p-nitroanilide + H2O
-
697471
Rattus norvegicus
Sar-Pro-Arg + p-nitroaniline
-
-
-
?
pH Optimum
pH Optimum Minimum
pH Optimum Maximum
Commentary
Organism
7.8
-
assay at
Rattus norvegicus
IC50 Value
IC50 Value
IC50 Value Maximum
Commentary
Organism
Inhibitor
Structure
additional information
-
cancer procoagulant activity from 4 independent prostate tumors is assayed, inhibition of FX-activating activity of cancer procoagulant-containing extracts by use of a polyclonal antiFVIIa antibody, samples obtained from 1-step purification of crude extract are tested for the presence of tissue factor or FVIIa activity in inhibition assay using antirat factor VIIa polyclonal antibodies, 0% inhibition of cancer procoagulant sample 1, 0.4% inhibition of cancer procoagulant sample 2, 6.6% inhibition of cancer procoagulant sample 3, 4.9% inhibition of cancer procoagulant sample 4
Rattus norvegicus
additional information
IC50 Value (protein specific)
IC50 Value
IC50 Value Maximum
Commentary
Organism
Inhibitor
Structure
additional information
-
cancer procoagulant activity from 4 independent prostate tumors is assayed, inhibition of FX-activating activity of cancer procoagulant-containing extracts by use of a polyclonal antiFVIIa antibody, samples obtained from 1-step purification of crude extract are tested for the presence of tissue factor or FVIIa activity in inhibition assay using antirat factor VIIa polyclonal antibodies, 0% inhibition of cancer procoagulant sample 1, 0.4% inhibition of cancer procoagulant sample 2, 6.6% inhibition of cancer procoagulant sample 3, 4.9% inhibition of cancer procoagulant sample 4
Rattus norvegicus
additional information
Inhibitors (protein specific)
Inhibitors
Commentary
Organism
Structure
antiCP polyclonal antibody
-
Rattus norvegicus
antiFVIIa polyclonal antibody
-
Rattus norvegicus
Natural Substrates/ Products (Substrates) (protein specific)
Natural Substrates
Organism
Commentary (Nat. Sub.)
Natural Products
Commentary (Nat. Pro.)
Organism (Nat. Pro.)
Reversibility
additional information
Rattus norvegicus
cancer procoagulant is a cysteine protease acting as an activator of coagulation factor X, the protein activates factor X in the absence of tissue factor and factor VII
?
-
-
-
additional information
Rattus norvegicus
rat and human cancer procoagulant activity bind similarly to antiCP antibodies
?
-
-
-
Purification (Commentary) (protein specific)
Commentary
Organism
harvested PA3 tumors are extracted in 0.02 M Tris (pH 7.8), after centrifugation extracts are purified by ion-exchange chromatography, fractions containing CP activity are desalted and concentrated by ultrafiltration on YM10 membrane and redissolved in 2-3 ml of 0.02 M Tris
Rattus norvegicus
Source Tissue (protein specific)
Source Tissue
Commentary
Organism
Textmining
prostate gland cancer cell
prostate tumor
Rattus norvegicus
-
Specific Activity [micromol/min/mg] (protein specific)
Specific Activity Minimum [Ámol/min/mg]
Specific Activity Maximum [Ámol/min/mg]
Commentary
Organism
additional information
-
enzyme has procoagulant activity
Rattus norvegicus
0.059
-
crude extract from independent PA3 tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
0.068
-
crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
0.078
-
crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
0.082
-
crude extract from independent PA3 rat prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
0.098
-
crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
2.26
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 33fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
2.32
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 30fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
4.91
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 50fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
7.7
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 133fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
16.6
-
extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 202fold purification, activity of samples is determined by using a 3-stage chromogenic assay
Rattus norvegicus
Substrates and Products (Substrate) (protein specific)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
additional information
cancer procoagulant is a cysteine protease acting as an activator of coagulation factor X, the protein activates factor X in the absence of tissue factor and factor VII
697471
Rattus norvegicus
?
-
-
-
-
additional information
rat and human cancer procoagulant activity bind similarly to antiCP antibodies
697471
Rattus norvegicus
?
-
-
-
-
Sar-Pro-Arg-p-nitroanilide + H2O
-
697471
Rattus norvegicus
Sar-Pro-Arg + p-nitroaniline
-
-
-
?
pH Optimum (protein specific)
pH Optimum Minimum
pH Optimum Maximum
Commentary
Organism
7.8
-
assay at
Rattus norvegicus
Other publictions for EC 3.4.22.26
No.
1st author
Pub Med
title
organims
journal
volume
pages
year
Activating Compound
Application
Cloned(Commentary)
Crystallization (Commentary)
Engineering
General Stability
Inhibitors
KM Value [mM]
Localization
Metals/Ions
Molecular Weight [Da]
Natural Substrates/ Products (Substrates)
Organic Solvent Stability
Organism
Oxidation Stability
Posttranslational Modification
Purification (Commentary)
Reaction
Renatured (Commentary)
Source Tissue
Specific Activity [micromol/min/mg]
Storage Stability
Substrates and Products (Substrate)
Subunits
Temperature Optimum [░C]
Temperature Range [░C]
Temperature Stability [░C]
Turnover Number [1/s]
pH Optimum
pH Range
pH Stability
Cofactor
Ki Value [mM]
pI Value
IC50 Value
Activating Compound (protein specific)
Application (protein specific)
Cloned(Commentary) (protein specific)
Cofactor (protein specific)
Crystallization (Commentary) (protein specific)
Engineering (protein specific)
General Stability (protein specific)
IC50 Value (protein specific)
Inhibitors (protein specific)
Ki Value [mM] (protein specific)
KM Value [mM] (protein specific)
Localization (protein specific)
Metals/Ions (protein specific)
Molecular Weight [Da] (protein specific)
Natural Substrates/ Products (Substrates) (protein specific)
Organic Solvent Stability (protein specific)
Oxidation Stability (protein specific)
Posttranslational Modification (protein specific)
Purification (Commentary) (protein specific)
Renatured (Commentary) (protein specific)
Source Tissue (protein specific)
Specific Activity [micromol/min/mg] (protein specific)
Storage Stability (protein specific)
Substrates and Products (Substrate) (protein specific)
Subunits (protein specific)
Temperature Optimum [░C] (protein specific)
Temperature Range [░C] (protein specific)
Temperature Stability [░C] (protein specific)
Turnover Number [1/s] (protein specific)
pH Optimum (protein specific)
pH Range (protein specific)
pH Stability (protein specific)
pI Value (protein specific)
Expression
General Information
General Information (protein specific)
Expression (protein specific)
KCat/KM [mM/s]
KCat/KM [mM/s] (protein specific)
733446
Kee
The effect of cancer procoagul ...
Homo sapiens
Biol. Chem.
393
113-121
2012
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
701292
Musallam
Incidence and prophylaxis of v ...
Homo sapiens
Thromb. Res.
123
679-686
2009
-
-
-
-
-
-
-
-
-
-
-
1
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
710603
Kaplinska
Cancer procoagulant (CP) analy ...
Homo sapiens
Thromb. Res.
124
364-367
2009
-
-
-
-
-
-
2
-
1
2
-
-
-
2
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
1
2
-
-
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
697471
Kamocka
Rat prostate tumors express ca ...
Rattus norvegicus
Comp. Med.
58
282-286
2008
-
-
-
-
-
-
2
-
-
-
-
2
-
3
-
-
1
-
-
2
11
-
3
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
1
2
-
-
-
-
-
2
-
-
-
1
-
2
11
-
3
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
679297
Kamocka
Effect of immunisation with ca ...
Homo sapiens
Clin. Exp. Med.
6
119-123
2006
-
1
-
-
-
-
1
-
-
1
-
-
-
4
-
-
1
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
-
-
1
-
-
-
-
-
1
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
679638
Szajda
Analysis of the relationship b ...
Homo sapiens
Eur. J. Gynaecol. Oncol.
27
495-499
2006
1
-
-
-
-
-
-
-
-
-
-
1
-
2
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
668075
Kazmierczak
Cancer procoagulant in patient ...
Homo sapiens
Blood Coagul. Fibrinolysis
16
543-547
2005
-
-
-
-
-
-
-
-
1
-
-
2
-
2
-
-
-
-
-
4
1
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
4
1
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
668137
Kamocka
Effect of cancer procoagulant ...
Homo sapiens
Cancer Lett.
222
89-94
2005
-
-
-
-
-
-
1
-
-
-
-
2
-
1
-
-
1
-
-
3
-
-
3
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
2
-
-
-
1
-
3
-
-
3
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
668476
Jozwik
The activity of cancer procoag ...
Homo sapiens
Eur. J. Gynaecol. Oncol.
26
407-410
2005
-
-
-
-
-
-
-
-
1
-
-
2
-
2
-
-
-
-
-
7
1
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
7
1
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
667302
Raasi
Properties of proteins in canc ...
Homo sapiens
Arch. Biochem. Biophys.
428
131-135
2004
-
-
-
-
-
-
2
-
-
2
-
1
-
1
-
-
1
-
-
1
1
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
2
-
1
-
-
-
1
-
1
1
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
651435
Mielicki
Biochemistry of cancer procoag ...
Homo sapiens, Oryctolagus cuniculus
Haemostasis
31 Suppl 1
8-10
2001
8
-
-
-
-
-
24
-
1
2
1
4
-
2
-
2
1
-
-
6
-
-
13
1
-
-
-
-
-
-
-
-
1
1
-
8
-
-
-
-
-
-
-
24
1
-
1
2
1
4
-
-
2
1
-
6
-
-
13
1
-
-
-
-
-
-
-
1
-
-
-
-
-
-
653983
Mielicki
Cancer procoagulant activity s ...
Homo sapiens
Thromb. Res.
87
251-256
1997
-
1
-
-
-
-
2
5
-
-
-
1
-
1
-
-
1
-
-
3
2
-
18
-
-
-
-
5
1
-
-
-
-
-
-
-
1
-
-
-
-
-
-
2
-
5
-
-
-
1
-
-
-
1
-
3
2
-
18
-
-
-
-
5
1
-
-
-
-
-
-
-
-
-
30160
Gordon
Cancer procoagulant ...
Homo sapiens, Rattus norvegicus
Methods Enzymol.
244
568-583
1994
2
-
-
-
-
6
26
-
-
8
2
-
-
2
2
2
-
-
-
7
-
-
2
-
2
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
6
-
26
-
-
-
8
2
-
-
2
2
-
-
7
-
-
2
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
30161
Mielicki
Effect of divalent ions on the ...
Homo sapiens
Arch. Biochem. Biophys.
314
165-170
1994
-
-
-
-
-
-
3
-
1
4
-
-
-
1
-
-
1
-
-
1
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
1
4
-
-
-
-
-
1
-
1
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30159
Moore
The purification and propertie ...
Mus musculus
Biochem. Biophys. Res. Commun.
184
819-824
1992
-
-
-
-
-
-
12
-
1
1
1
1
-
3
-
-
1
-
-
6
-
1
4
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12
-
-
1
1
1
1
-
-
-
1
-
6
-
1
4
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
30158
Falanga
Inhibition of cancer procoagul ...
Oryctolagus cuniculus
Thromb. Res.
54
389-398
1989
-
-
-
-
-
-
2
-
-
-
-
-
-
1
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30157
Falanga
Several murine metastasizing t ...
Mus musculus, Oryctolagus cuniculus
Int. J. Cancer
39
774-777
1987
-
-
-
-
-
-
-
-
-
-
-
4
-
4
-
-
-
-
-
8
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
8
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30156
Falanga
Isolation and characterization ...
Oryctolagus cuniculus
Biochemistry
24
5558-5567
1985
-
-
-
-
-
-
2
-
-
-
2
1
-
2
-
1
1
-
-
3
-
-
2
1
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
2
1
-
-
1
1
-
3
-
-
2
1
1
-
-
-
1
-
-
-
-
-
-
-
-
-